Phase 3 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to take part voluntarily, have read and signed a consent form, and agree to follow the study procedures
- You have plaque psoriasis that your doctor considers suitable for systemic (whole-body) treatment, and your condition has been stable — with no major flare-ups or changes — for at least 6 months before signing the consent form
- During the screening period and before taking the study medication for the first time, your psoriasis covers at least 10% of your body surface area and scores at least 3 on the doctor's overall assessment scale and at least 12 on the psoriasis severity scoring scale
- Your blood tests and urine tests come back broadly within normal ranges
Who may not be able to join:
- You have a specific type of psoriasis other than plaque psoriasis, such as the red skin (erythrodermic), pus-filled (pustular), raindrop-shaped (guttate), skin-fold (reverse), or medication-triggered (drug-induced) forms
- You have other skin conditions, such as eczema, that could make it difficult for doctors to accurately assess how well the treatment is working
- You have a history of shingles or cold sore/genital herpes infections, or you currently have one of these infections during the screening period
- You have a history of tuberculosis (TB), currently have active TB, have latent (dormant) TB, or show signs that may suggest a TB infection
- Your doctor identifies any other reason they feel makes it unsuitable for you to take part in this study (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jianzhong Zhang, Study Official is required by the WHO and ICMJE.
Phone: 021-50663661
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The percentage of subjects with at least 90% improvement in PASI
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.